BioCentury
ARTICLE | Financial News

Anti-infectives company MicuRx raises RMB100M

December 6, 2017 9:03 PM UTC

MicuRx Pharmaceuticals Inc. (Hayward, Calif.) raised RMB100 million ($15.1 million) in a private placement led by existing investors Delian Capital and BVCF.

The biotech's lead candidates are contezolid (MRX-1) and contezolid acefosamil (MRX-4). MRX-1 is in Phase III testing in China to treat complicated skin and skin structure infections (cSSSIs). The candidate is an oral oxazolidinone antibiotic and analog of linezolid, a bacterial protein biosynthesis inhibitor...